ESR1 and breast carcinoma: Other treatment possibilities include more targeted therapies—cyclin-dependent kinase 4 and 6 inhibitors (palbociclib, ribociclib, abemaciclib) that were recently approved by FDA in combination with hormone therapies for treatment of ER+ Her2- advanced breast cancer [86].